




Sensitive GATA1 mutation screening reliably identifies neonates
with Down syndrome at risk for myeloid leukemia
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To the Editor:
Children with Down syndrome (DS) have a higher chance
of developing myeloid neoplasms as compared to healthy
children [1]. Therefore, the World Health Organization
(WHO) classifies myeloid neoplasms associated with DS as
separate from other myeloid neoplasms. The most recent
WHO classification defines transient abnormal myelopoi-
esis (TAM) in children with DS as “increased peripheral
blood (PB) blast cells in a neonate with DS”. No minimal
percentage of blasts is defined to specify “increased” [2].
Using this definition, about 5–10% of neonates with DS
develop TAM [3]. Approximately 1% of patients with DS
develop myeloid leukemia of DS (ML DS) between 1 and 4
years of age. Approximately 20% of children diagnosed
with TAM will develop ML DS [4].
Both TAM and ML DS are associated with mutations in
the GATA1 gene [5]. Mutations in GATA1 result in a
truncated protein (GATA1s). The majority of mutations are
localized in exon 2 or 3. GATA1 mutations are patient-
specific, and identical in patients diagnosed with both TAM
and ML DS. TAM is usually diagnosed when the patient is
~1 week old and blasts disappear spontaneously after
4 weeks in around 80% of children [3]. Approximately 20%
of children develop serious symptoms and around 10% of
children with TAM die in the first months of life as a result
of TAM [3]. Therefore, in some cases, treatment is indi-
cated using low dose cytarabine. This treatment has
improved the outcome of children with severe TAM [3].
The aim of this study was to define a population-based
frequency of TAM in DS newborns. The Dutch Pediatric
Surveillance Unit (DPSU) registers newborns with DS and
TAM screening was added to this registration from Jan 1,
2008, until Jan 1, 2013 (Erasmus MC MEC-2007-168,
Netherlands Trial Register NL1587). Based on the live birth
prevalence of DS in the Netherlands, an estimated 1211 DS
children were born in the Netherlands during the screening
period. Between 2008 and 2013, 803 neonates with DS
were included in the DPSU registry. Therefore ~66% of the
neonates with DS were registered. Of the 803 registered
neonates, TAM screening blood samples were received for
368 neonates (46% of the registered cases). The low
inclusion rate could give rise to a selection bias, as pedia-
tricians are probably more likely to include neonates with
symptoms or abnormal PB values compared to healthy DS
neonates. Therefore, the incidence of TAM could be over-
estimated in this study.
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We screened 368 PB samples from DS neonates for
TAM within the first 4 weeks of life using morphology and
flow cytometry (technical details in Supplemental methods).
The median postnatal age at screening was 5.0 days
(p25–p75 0–11 days) and their clinical characteristics are
detailed in Table 1. In 45 of the 368 cases screened (12%),
blasts were detected (Fig. 1). The median blast percentage
using morphology was 10% (range 1–91%). Of these neo-
nates, 34 had at least 5% blasts (9.1%) and 31 had at least
10% blasts (8.4%). Six children died in the neonatal period,
four due to TAM related complications, one of asphyxia,
and one as a result of multiple congenital abnormalities. All
children who had peripheral blasts were offered inclusion in
the Flasinski study [6].
Nine children with TAM received at least one course of
cytarabine (range 1–3 courses). Treatment was initiated
because of clinical symptoms. Three of these nine treated
children died during or shortly after treatment, all related to
the TAM (two patients as a result of sepsis, one of liver
failure).
In 30 of 42 neonates (71%) with detectable blasts and
available DNA, a GATA1 exon 2 mutation was detected by
Sanger sequencing (Ss). As Ss can be false negative in cases
with blast percentages below ~20%, targeted deep sequen-
cing (TDS) was performed on the 12 cases with detectable
blasts but without a GATA1 mutation by Ss. Furthermore, in
1 of the 3 cases without available DNA initially, the
material was found and analyzed with TDS. In 8 out of
these 13 patients, a GATA1 exon 2 mutation was detected
using TDS (median mutational frequency 6.6%). No exon 3
mutations were detected. Overall, 38 of 43 neonates with
blasts tested using Ss and/or TDS were positive for a
GATA1 mutation (88%).
In addition, 319 of the 323 PB samples of DS neonates
without blasts, were screened for GATA1 mutations using
TDS. In four cases no material for analysis was available. In
17 cases an exon 2 mutation was detected (5.3%). There-
fore, the total number of cases with a GATA1 mutation was
55 (15%). No exon 3 mutations were detected. There was
one case with 9% blasts where no GATA1 exon 2 or 3
mutation was detected.
As the WHO does not specify the percentage of blasts to
define TAM, different groups use different blast percentages
ranging from ≥1% to ≥10% to define TAM in neonates with
DS [6–9]. Therefore, we defined TAM as either >5% blasts
(as determined by immunophenotyping or morphology),
and/or detection of a GATA1 mutation. Using this definition
resulted in 34 neonates with TAM as defined by immuno-
phenotyping and morphology (9.1%), and 55 neonates with
a mutation in GATA1 (15.2%), for a total of 56 patients with
TAM. This resulted in a sensitivity of 58% and a specificity
of 100% for immunophenotyping and a sensitivity of 95%
and a specificity of 100% for GATA1 screening either
through Ss or TDS. One patient had 9% blasts, liver
fibrosis, and severe cholestasis but we could not detect a
GATA1 mutation. No other cause of liver fibrosis was
identified. The patient was treated with cytarabine but
despite this treatment ultimately died. We cannot exclude
that a rare GATA1 mutation occurred outside the screened
region in this patient, although this has not been previously
described [10].
The recent study by Roberts et al. described a cohort of
200 hospitalized DS neonates screened for TAM and
reported 17/200 TAM cases by conventional screening and
an additional 18/88 “silent” TAM cases identified using
NGS, leading to an overall frequency GATA1 mutations
29% [11]. In our study, the overall frequency of GATA1
mutations was lower, in total 15% (55/368).
Fifteen children with Down syndrome who were born
in the Netherlands during the screening period were
diagnosed with ML DS between 2008 and February 2019.
As the DCOG registers all cases of pediatric leukemia in
the Netherlands, this is a population-based number.
Therefore, 1.2% (15/1211) of the neonates with DS
developed ML DS. Of these 15 children, 8 had been
screened for TAM after birth. Therefore, the frequency of
Table 1 The clinical characteristics of Down syndrome (DS) neonates
in this study. In the “no blasts detected” column are the patients who
were screened and in whom no blasts were detected using
immunophenotyping and morphology, in the “blasts detected”





Total number of patients 323 45
Sex (male) 177/323 (55%) 19/36 (53%)
Median pregnancy duration
(weeks, range)
38 (31–42) 37.5 (33–40)
Died in the neonatal period 3/108 (2.8%) 6/21 (29%)
First postnatal complete blood count
Hemoglobin (mmol/L,
median, p25–p75)
12.7 (10.7–13.9) 11.0 (9.4–12.4)
White blood cell count
(median, *10 9/L, p25–p75)
15.1 (10.7–21) 20.1 (12.4–37.3)
Thrombocyte count (median,
*10 9/L, p25–p75)




Hydrops fetalis 0 3/14 (21%)
Pleural effusion 2/170 (1.2%) 1/14 (7%)
Pericardial effusion 2/168 (1.2%) 2/14(14%)
Ascites 0 3/14 (21%)
ML DS (during follow-up) 2/323 (0.6%) 6/45 (13%)
DS ALL (during follow-up) 3/323 (0.9%) 1/45 (2.2%)
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ML DS in the screened cohort was 2.1%, this was not
significantly different from the unscreened cohort (p=
0.07). In six cases blasts were detected after birth, and two
out of these six children had symptomatic TAM treated
with two courses of cytarabine. Two DS neonates later
diagnosed with ML DS, had been screened but no blasts
were detected. However, in both of these cases, the neo-
natal PB samples harbored GATA1 exon 2 mutations
detected through TDS. In the ML DS cells of these
patients, exon 2 mutations identical to the mutations at
birth were detected.
TAM is an important predictor of ML DS as most
patients who developed ML DS in this study had peripheral
blasts and all had a mutation in GATA1 in the neonatal
period. Although no preventive therapy of ML DS has been
discovered until now, early detection of ML DS can help
improve outcome as patients may not have developed
symptoms as yet at the time of detection, and hence may be
in a better general condition when they start chemotherapy.
Furthermore, being able to define which neonates with DS
are at risk of developing ML DS is relevant information for
parents, as parents of children not fulfilling TAM criteria
can be informed that the risk for ML DS is extremely low.
However, the increased risk for acute lymphoblastic leu-
kemia (ALL) in DS children still applies. Therefore, we
advocate screening all DS neonates for peripheral
blood blasts and GATA1 mutations, using sensitive PCR
techniques.
In light of the current study and the study by Roberts
et al., we recommend updating the TAM definition in the
next revision of the WHO classification. First of all, as there
is no minimum number of blasts defined, this can lead to
overdiagnosis, as neonates may often have benign immature
cells in their PB. Furthermore, all patients who developed
ML DS and were included in this study had a GATA1
mutation in the neonatal period. Thus, we recommend to re-
define TAM as “the presence of at least 5% blasts defined
by immunophenotyping or morphology and/or the presence
of a GATA1 mutation in a neonate with DS.” This would
lead to the identification of a group of neonates at risk for
the development of ML DS who can receive close follow-
up for early detection of ML DS.
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Fig. 1 This flow chart describes the results of TAM screening in
368 Dutch newborns with Down syndrome (DS). An estimated 1158
neonates with DS were born during the study period in the Nether-
lands. 368 neonates were screened using peripheral blood morphology
and immunophenotyping. If TAM was diagnosed, GATA1 mutation
screening was performed using Sanger sequencing (Ss). In addition,
using targeted deep sequencing (TDS) as a more sensitive screening
method, we retrospectively screened all TAM negative cases and all
TAM cases without a GATA1 mutation for GATA1 mutations. All
children were followed until the age of 4 years to see if they developed
ML DS. TAM transient myeloproliferative disorder, ML DS myeloid
leukemia of DS.
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